Roadmap to functional cure of chronic hepatitis B: An expert consensus

2019 ◽  
Vol 26 (10) ◽  
pp. 1146-1155 ◽  
Author(s):  
Qin Ning ◽  
Di Wu ◽  
Gui-Qiang Wang ◽  
Hong Ren ◽  
Zhi-Liang Gao ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Expert Consensus ◽  
Functional Cure

scholarly journals Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 216 ◽  
Author(s):  
Sayeh Ezzikouri ◽  
Mohammad Enamul Hoque Kayesh ◽  
Soumaya Benjelloun ◽  
Michinori Kohara ◽  
Kyoko Tsukiyama-Kohara
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Adaptive Immunity ◽  
Chronic Hepatitis B ◽  
Immune Modulation ◽  
Therapeutic Strategies ◽  
Functional Cure ◽  
Innate And Adaptive Immunity ◽  
Promising Target ◽  
Current Therapies

Despite the availability of an effective preventive vaccine for hepatitis B virus (HBV) for over 38 years, chronic HBV (CHB) infection remains a global health burden with around 257 million patients. The ideal treatment goal for CHB infection would be to achieve complete cure; however, current therapies such as peg-interferon and nucleos(t)ide analogs are unable to achieve the functional cure, the newly set target for HBV chronic infection. Considering the fact functional cure has been accepted as an endpoint in the treatment of chronic hepatitis B by scientific committee, the development of alternative therapeutic strategies is urgently needed to functionally cure CHB infection. A promising target for future therapeutic strategies is immune modulation to restore dysfunctional HBV-specific immunity. In this review, we provide an overview of the progress in alternative therapeutic strategies, including immune-based therapeutic approaches that enhance host innate and adaptive immunity to achieve and increase the functional cure from CHB infection.

scholarly journals Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

2021 ◽  
Author(s):  
Hannah S.J. Choi ◽  
Alexander Tonthat ◽  
Harry L.A. Janssen ◽  
Norah A. Terrault
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Novel Therapies ◽  
Functional Cure

scholarly journals The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis B

2020 ◽  
Vol 19 (4) ◽  
pp. 362-369 ◽  
Author(s):  
Jeremy S Nayagam ◽  
Zillah C Cargill ◽  
Kosh Agarwal
Keyword(s):  
Clinical Trials ◽  
Chronic Hepatitis ◽  
Rna Interference ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Early Phase ◽  
Safety Data ◽  
Functional Cure ◽  
Wide Range ◽  
Early Phase Clinical Trials

Abstract Purpose of Review Current treatments for chronic hepatitis B (CHB) are associated with low rates of cure. Functional cure has been accepted as a viable treatment end point in CHB. There have been substantial advances in the field of RNA interference (RNAi) therapeutics across a wide range of specialties, and the clinical pipeline now encompasses CHB. This review will highlight some of the challenges in therapeutic development, the data for RNAi in CHB, and future directions for the field. Recent Findings Early phase clinical trials have reported good safety data for RNAi therapies in CHB and demonstrated significant reductions in quantitative HBsAg levels (qHBsAg). Animal models however suggest that in HBeAg-negative individuals, HBsAg may be derived from hepatitis B DNA integrated into the host genome, which cannot be targeted by current RNAi therapies, and may prove to be a limitation. Preliminary data is being presented from combination therapy, which may result in more robust reductions in qHBsAg; however, trials are in the early stages of recruitment. Summary Despite promising data that RNAi may be an effective therapeutic strategy in CHB, it is unlikely to be in the form of monotherapy. The goal for the community will be to find the right combination of RNAi therapy with other antiviral or immunomodulatory agents, to achieve functional cure with a cessation of therapy. Early phase clinical trials are continuing to recruit, and data from combination studies will provide a “pivot point” in determining whether RNAi therapies can provide a backbone to finite duration and curative CHB regimens.

Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B

2020 ◽  
Vol 73 (4) ◽  
pp. 800-806 ◽  
Author(s):  
Lung-Yi Mak ◽  
Rex Wan-Hin Hui ◽  
James Fung ◽  
Fen Liu ◽  
Danny Ka-Ho Wong ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Hepatic Steatosis ◽  
Chronic Hepatitis B ◽  
Functional Cure ◽  
Fibrosis Progression
Sign in / Sign up

Export Citation Format

Share Document